Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report Q2, 2020

April - June 2020 Second quarter 2020 · Net sales amounted to MSEK 2.7 (2.9) · EBITDA before extraordinary costs amounted to MSEK -8.9 (-11.0) · EBT amounted to MSEK 12.2* (-12.4) · Earnings per share before dilutions amounted to SEK  0.13 (-0.22) · SpectrumOne AB (publ) completes acquisition of Cloud Explorers AS · SpectrumOne AB announces the acquisition of the data analytics and consulting company Qbim AB · The Board of Directors in SpectrumOne AB decides on a free of payment rights issue of units and directed issue of units Significant events after the

Nasdaq Stockholm Disciplinary Board imposes a penalty of 4 annual fees on AVTECH Sweden AB (publ) for deficiencies in the following of information disclosure rules

AVTECH Sweden AB (publ) (the "Company") has been informed of a decision from the Disciplinary Board of Nasdaq Stockholm that the Company is required to pay a penalty of 4  annual fees  a' SEK 100,000 for not having published information in accordance with the Regulations on two occasions. The first occasion is the agreement with Norwegian on 11 December 2018 where a minor delay occurred and where the decision to postpone publication was not properly documented. The second occasion is the publication of the notice of the Annual General Meeting on 2 April 2020, where full information on

Report from the Annual General Meeting of EQL Pharma AB (publ) on August 27th, 2020

At EQL Pharma's Annual General Meeting, which was held in Lund, August 27[th], 2020, the following decisions were made:Adoption of the balance sheet and income statement, disposition regarding the Company’s results The annual general meeting resolved to adopt the balance sheet and income statement and the consolidated balance sheet and income statement for the financial year 2019-04-01 – 2020-03-31. The annual general meeting also resolved that no dividends shall be paid for the financial year 2019/2020.  Discharge from liability for the Board of Directors and the Managing Director

Welcome to the launch of Star Wine List in Bangkok!

Star Wine List is the digital guide to great wine bars and wine restaurants, selected by wine professionals. We started in Stockholm in 2017 and are today covering top cities in more than 25 countries. In every city, we ask top sommeliers and wine personalities to guide us and other wine lovers to their favorite wine places. For example, the 2016 Best Sommelier of the World Arvid Rosengren has produced our New York guide. Rasmus Poll (Central Group) and Fredrik Wohlrabe (Restaurant Gaa) are our Bangkok ambassadors and they have curated our first Bangkok selection. Our Bangkok

Star Wine List puts Bangkok on global wine map

Star Wine List, the award-winning guide to great wine bars and wine restaurants, has published the wine lover's guide to Bangkok. The guide is curated by Star Wine list ambassadors Rasmus Poll from Central Group and Fredrik Wohlrabe, awarded Head Sommelier at Gaa.“I am really happy that Star Wine List is coming to Bangkok! Though the wine scene is relatively young; the sommeliers and wine importers are doing a great job and it is growing day by day. I am proud to share some of my favorite wine spots in Bangkok,” says Gaa Head Sommelier Fredrik Wohlrabe. Star Wine List, on app and

New number of shares and votes in Catena Media plc

Catena Media plc (Nasdaq Stockholm: CTM)  Catena Media plc (“Catena Media” or the “Company”) announces that the number of shares and votes in the Company has increased by 5,124,004 due to the exercise of Catena Media’s warrants (CTM TO1) (the “Warrants”) during the first Warrant exercise period.As announced on 21 July 2020, 5,124.004 Warrants were used to subscribe for the same number of new ordinary shares in Catena Media during the first Warrant exercise period. The new shares were registered with Maltese authorities in August 2020.  Through the exercise of Warrants during the first

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In August, at the request of shareholders 49 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,257,959,757.The total number of registered shares in the company amounts to 702,342,489 of which 61,735,252 are Class A shares

AFRICA OIL RECEIVES FOURTH DIVIDEND FROM ITS NIGERIAN ASSET

Vancouver, BC, August 31, 2020 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“AOI”, “Africa Oil” or “the Company”) is pleased to announce that it has received its fourth dividend from Prime Oil and Gas B.V. (“Prime”), a company that holds interests in deepwater Nigeria production and development assets. Prime has distributed a US$50 million dividend with a net payment to Africa Oil of US$25 million related to its 50% interest. The Company has applied US$17.7 million of this dividend to pay down the BTG term loan, reducing the outstanding balance to US$176.9 million. The

Hansa Biopharma announces participation in Fall conferences and an updated financial calendar

Hansa Biopharma has been invited to participate in several leading global healthcare conferences during the Fall 2020. Hansa Biopharma will host a Capital Markets Day event on October 29, 2020 in Copenhagen as a combined virtual/physical setup.Lund, Sweden August 31, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company’s management team will present at the following upcoming investor conferences in September: · Pareto Securities Health Care Conference on Thursday September 3, 2020, at 15:30 CET ·

Interim report April - June 2020

Quant releases the interim report for April - June 2020.April-June · Net sales for the period decreased by 16.2% to EUR 41.2 (49.1) million. Organically, net sales decreased by 13.1% · During the quarter, the contract portfolio decreased although one contract was renewed and three contracts were won, but where two contracts were lost or exited. Portfolio run rate annualized net sales at the end of the quarter was EUR 169.2 million, compared to EUR 175.1 million during the first quarter of 2020 · Operating loss amounted to EUR -1.0 million, compared to a loss of EUR -0.8 million

Increased number of shares and votes in Qliro Group

Qliro Group AB (publ) (“Qliro Group”) today announces that the total number of shares and votes in Qliro Group amounts to 184,949,730. The increase in number of shares refers to the directed issue of 29,954,951 ordinary shares resolved upon by the board of directors on 26 August 2020.As of 31 August 2020, the total number of shares and votes in Qliro Group amounts to 184,949,730, of which 179,729,730 are ordinary shares and 5,220,000 are class C shares. All class C shares are held as treasury shares by Qliro Group. This information is information that Qliro Group AB (publ) is obliged to

Stina Lindh Hök new CEO of Nyfosa

The Board of Nyfosa has appointed Stina Lindh Hök as new CEO of Nyfosa AB. She will replace Jens Engwall who has been the company’s CEO since the spin-off from Hemfosa in autumn 2018. Stina is currently Nyfosa’s Chief Operating Officer and has solid experience from transaction-based property operations and business development. Stina will take up her position as CEO on October 26, 2020. Stina Lindh Hök holds a Master of Science in Engineering from the KTH Royal Institute of Technology in Stockholm. She has served as Chief Operating Officer (COO) of Nyfosa since the company was formed

MPC Container Ships ASA reports Q2 and six-month 2020 results

· Q2 2020 operating revenue USD 39.1 million. H1 2020 operating revenue USD 85.1 million. · Q2 2020 EBITDA USD 1.4 million. H1 2020 EBITDA USD 8.9 million. · Q2 2020 net loss USD 17.6 million. H1 2020 net loss USD 28.3 million. · Equity ratio 55.5% as of 30 June 2020. Oslo, 31 August 2020 Q2 and six-month 2020 results: MPC Container Ships ASA ("MPCC" or the "Company", together with its subsidiaries the "Group") today published its unaudited financial report for the six-month period ended 30 June 2020. The Group reports a net loss of USD 17.6 million for Q2 2020. ·

Interim report April - June 2020

The full Interim report is available on Brighter's website https://brighter.se. The report is also attached as a pdf file to this press release. April – June 2020 · Net sales amounted to SEK 2,128 thousand (0). · Operating result amounted to SEK -46,362 thousand (-19,467). · Earnings before tax amounted to SEK -53,765 thousand (-23,671). · Earnings per share, before and after dilution amounted to SEK -0.18 (-0.29). Among the reasons for the higher loss was amortization of capitalized development and depreciation on equipment and installations now ready for use in

Implantica announces its intention to launch an initial public offering of Swedish Depository Receipts on Nasdaq First North Premier Growth Market in Stockholm

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE READ "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.Implantica AG[1] (“Implantica” or the “Company”), a medtech group with operations within the implantable medical device and eHealth markets, today announces its intention to launch an initial public

Loudspring: Half-year review 1 January – 30 June 2020 (unaudited)

Loudspring Oyj Company release 31 August 2020 at 8:30 (EEST) The full 2020 half-year report in PDF can be found here.  LOUDSPRING IN BRIEF We manage a portfolio of Nordic growth companies that are making a big environmental impact globally. We believe that as our entrepreneurial teams are contributing to solving some of the biggest challenges our planet faces, this translates into a unique opportunity for growing profitable businesses.  Loudspring is an investment group focused on saving natural resources. INVESTMENTS Eagle

NCC sells the Keilaniemi Next office building in Helsinki, Finland to Warburg-HIH Invest Real Estate

NCC has sold the office building Next, which will become the headquarters of Fiskars Group when finished in late 2021, to a fund administered by German Warburg-HIH Invest Real Estate (Warburg-HIH Invest). Illustration: SARC Architects - In Keilaniemi Next, we have worked closely together with all parties to develop an office project with a modern and sustainable working environment. Warburg-HIH Invest has chosen this project as its first investment coming back to Finland and we are very excited about our collaboration, says Petri Bergström, Head of NCC Property Development

Read original

Targovax ASA: Settlement of restricted stock units by primary insider and resolution to increase the share capital

Oslo, 31 August 2020: The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") has resolved to increase the share capital of the Company following the completion of a settlement period for vested restricted stock units ("RSUs"). The settlement period commenced on 21 August 2020 at 10:00 hours (CEST) and ended on 28 August 2020 at 10:00 hours (CEST). In total were 88,272 RSUs settled, giving the RSU holders the right to subscribe for in total 88,272 shares, each with a par value of NOK 0.10, at a subscription price of NOK 0.10 per share. 1. Settlement of RSUs by

ZUTEC SIGNS SEK3.2M AGREEMENTS FOR THE NATIONAL CHILDREN’S HOSPITAL

Zutec Holding AB (publ) (“Zutec") today announced that it has recently signed contracts with Linesight for the National Children’s Hospital (“NCH”) in Dublin, Ireland. The contracts are typical Infrastructure Solutions agreements consisting of both services and software license. In aggregate the outstanding value of the contract is SEK3.2m and the contracts expire between the end of 2022 and middle of 2023.  “We are pleased to be working with the team at the National Children’s Hospital and we are proud to be expanding our partnership. The Zutec platform is now being used on a variety of

High customer satisfaction with Picosun’s new service and support model

ESPOO, Finland, 31[st] August 2020 – Picosun Group’s growth strategy is based on strong expansion into industrial ALD markets. To support this strategy, special emphasis has been placed on strengthening the Group’s global service organization. The investment has paid itself back in the form of high level of customer satisfaction, despite the challenges caused by the global covid-19 pandemic especially in traveling and logistics. “Due to the reinforced localization of our service and support units, our service engineers’ utilization level has been more than 85% in the past six months, and

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Nordic Waterproofing Holding A/S’ shares

In accordance with article 19 of Market Abuse Regulation, Nordic Waterproofing Holding A/S, hereby notifies receipt of information of the following transactions in the company's shares made by persons discharging managerial responsibilities and persons closely associated with them.1 Details of the person discharging managerial responsibilities/person closely associated   a) Name: Martin Ellis 2. Reason for the notification a) Position/Status: President and CEO of Nordic Waterproofing Holding A/S, b) Initial notification/Amendment: Initial notification 3. Details of the issuer

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

STOCKHOLM — August 29, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides´ New Drug Application seeking approval of melflufen (INN melphalan flufenamide), in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD-38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients). The FDA has set a PDUFA-date (Prescription Drug

Correction: Notice to participate at the Annual General Meeting of Shareholders of DDM Holding AG

A correction has been issued in relation to the Notice to participate at the Annual General Meeting of Shareholders of DDM Holding AG to remove the reference to the EU Market Abuse Regulation. The Swiss Federal Government has declared a “special situation” in Switzerland due to the COVID-19 pandemic. Protecting the health of our shareholders and employees is a priority for us. Therefore, the personal attendance of the shareholders at the annual general shareholders’ meeting (the “AGM”) of DDM Holding AG (First North Growth Market: DDM), (the “Company”) is not possible. This year’s AGM

There are no items matching the current filter
There are no more items matching the current filter
Back to top